Barrow Neurological Institute
Neurology
Marwan Noel Sabbagh is board certified neurologist and geriatric neurologist and is considered one of the leading experts in Alzheimer’s and dementia. Dr Sabbagh has dedicated his career to finding a cure for Alzheimer’s and other age-related neurodegenerative diseases. Dr Sabbagh is a leading investigator for many prominent national Alzheimer’s prevention and treatment trials. Dr Sabbagh is on the editorial board for Journal of Alzheimer's Disease and Alzheimer’s and Dementia TRCI. He is editor in chief of Neurology and Therapy. He has authored and co-authored almost 400 medical and scientific articles on Alzheimer’s research. Dr Sabbagh earned his undergraduate degree from the University of California, Berkeley and his medical degree from the University of Arizona in Tucson. He received his residency training in neurology at Baylor College of Medicine, Houston, Texas, and completed his fellowship in geriatric neurology and dementia at the University of California, San Diego School of Medicine, where he served on the faculty as assistant professor. Before rejoining the faculty of the Barrow Neurological Institute, he was the Camille and Larry Ruvo Endowed Chair for Brain Health and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. Prior to that, he was the director of the Banner Sun Health Research Institute.

Moderator of 1 Session

SPONSORED SYMPOSIUM
Session Type
SPONSORED SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
02:00 PM - 03:40 PM
Room
ONSITE PLENARY: 115-117
Session Description
The future of AD and PD – reaching beyond symptom control -Supported by Novo Nordisk

Session Description:

This symposium will introduce the need for new treatments for Alzheimer’s disease and Parkinson’s disease that go beyond symptomatic control and potentially treat the underlying causes of each disease. During this session, the pathophysiology of Alzheimer’s disease will be examined and drug targets other than amyloid and tau considered, including key data published on these targets to date. There will also be a presentation on neuroinflammation as an aspect of neurodegenerative diseases and a potential target for the treatment of both Alzheimer’s disease and Parkinson’s disease. Finally current treatments for Parkinson’s disease will be discussed briefly, as well as treatments currently being investigated in clinical trials, to provide a perspective on how the treatment landscape may change from symptomatic control to treatment in the future. These topics will be discussed by the expert faculty, who will also address any questions from attendees.

Presenter of 4 Presentations

Panel discussion: What does the future hold for people with AD and PD? Summary and meeting close

Session Type
SPONSORED SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
02:00 PM - 03:40 PM
Room
ONSITE PLENARY: 115-117
Lecture Time
03:17 PM - 03:37 PM

Summary and meeting close

Session Type
SPONSORED SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
02:00 PM - 03:40 PM
Room
ONSITE PLENARY: 115-117
Lecture Time
03:37 PM - 03:40 PM

Welcome and introduction

Session Type
SPONSORED SYMPOSIUM
Date
Wed, 16.03.2022
Session Time
02:00 PM - 03:40 PM
Room
ONSITE PLENARY: 115-117
Lecture Time
02:00 PM - 02:10 PM

KEY TRIAL DESIGN ASPECTS AND CLINICAL OUTCOMES OF THE LECANEMAB PHASE 2 TRIAL AND OPEN-LABEL EXTENSION IN EARLY ALZHEIMER’S DISEASE

Session Type
SYMPOSIUM
Date
Fri, 18.03.2022
Session Time
05:15 PM - 07:15 PM
Room
ONSITE PLENARY: 115-117
Lecture Time
05:40 PM - 05:55 PM

Abstract

Aims

Lecanemab is a humanized IgG1 monoclonal antibody that selectively targets soluble aggregated Aβ species. Key design features and latest results will be presented from a large, double-blind, placebo-controlled, randomized 18-month phase 2 proof-of-concept Core study (Study 201) with a Bayesian design and an open-label extension (OLE) recently conducted in early Alzheimer’s disease (AD).

Methods

In this presentation, the design and latest results from the lecanemab Study 201 Core, in which patients were randomized to five dose regimens or placebo will be reviewed. The latest data from the open-label extension (OLE) of Study 201, which was initiated to allow patients to receive open-label lecanemab 10mg/kg-biweekly for up to 24 months will also be reviewed.

Results

Lecanemab treatment can be initiated without titration and results in rapid and thorough amyloid reduction correlating with clinical benefit. Amyloid reduction achieved within 3 months and clinical efficacy within 6 months of treatment. Benefit in early AD patients is maintained after treatment discontinuation, suggesting potential disease modifying effects. ARIA-E and symptomatic ARIA rates were low in the Core and OLE. These data are supportive of important therapeutic effects and are supported by changes in key biomarkers as discussed by the next speaker. These findings will be further evaluated in the phase 3 Clarity AD trial which is ongoing.

Conclusions

The findings from Study 201 Core and OLE suggest that lecanemab 10mg/kg biweekly can be initiated to elicit rapid reduction of brain amyloid at the onset of treatment with relatively low incidence and severity of ARIA-E.

Hide